Search
AVI-4557
go.drugbank.com/drugs/DB05447Experimentalin clearance and an increase in maximal blood concentration (Cmax). … Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and longer availability of the drug in the patient's system through a decrease
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalThe development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.
Vapendavir
go.drugbank.com/drugs/DB05181InvestigationalBTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.
Posizolid
go.drugbank.com/drugs/DB04850InvestigationalIn July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though … Posizolid (AZD2563) is an oxazolidinone antibiotic.
Pexelizumab
go.drugbank.com/drugs/DB04949InvestigationalPexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Butriptyline
go.drugbank.com/drugs/DB09016ApprovedWithdrawnButriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.
AVAC
go.drugbank.com/drugs/DB05441ExperimentalAVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Mosedipimod
go.drugbank.com/drugs/DB12592InvestigationalMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.